

Quercetin

Teil 2 – Biologische Wirksamkeit, Sicherheit und Toxizität

Elisabeth Wisker, Kiel; Sarah Egert, Bonn

Literatur

1. Boots AW, Haenen GR, Bast A (2008) Health effects of quercetin: from antioxidant to nutraceutical. *Eur J Pharmacol* 585: 325–337
2. Williams RJ, Spencer JP, Rice-Evans C (2004) Flavonoids: antioxidants or signalling molecules? *Free Radic Biol Med* 36: 838–849
3. Brown JE, Khodr H, Hider RC, Rice-Evans CA (1998) Structural dependence of flavonoid interactions with Cu²⁺ ions: implications for their antioxidant properties. *Biochem J* 330 (Pt 3): 1173–1178
4. McPhail DB, Hartley RC, Gardner PT, Duthie GG (2003) Kinetic and stoichiometric assessment of the antioxidant activity of flavonoids by electron spin resonance spectroscopy. *J Agric Food Chem* 51: 1684–1690
5. Loke WM, Proudfoot JM, Stewart S et al. (2008) Metabolic transformation has a profound effect on anti-inflammatory activity of flavonoids such as quercetin: lack of association between antioxidant and lipoxygenase inhibitory activity. *Biochem Pharmacol* 75: 1045–1053
6. Yamamoto N, Moon JH, Tshushida T et al. (1999) Inhibitory effect of quercetin metabolites and their related derivatives on copper ion-induced lipid peroxidation in human low-density lipoprotein. *Arch Biochem Biophys* 372: 347–354
7. Moon JH, Tshushida T, Nakahara K, Terao J (2001) Identification of quercetin 3-O-beta-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. *Free Radic Biol Med* 30: 1274–1285
8. Egert S, Wolffram S, Bosity-Westphal A et al. (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. *J Nutr* 138: 1615–1621
9. Conquer JA, Maiani G, Azzini E et al. (1998) Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. *J Nutr* 128: 593–597
10. Shanely RA, Knab AM, Nieman DC et al. (2010) Quercetin supplementation does not alter antioxidant status in humans. *Free Radic Res* 44: 224–231
11. Edwards RL, Lyon T, Litwin SE et al. (2007) Quercetin reduces blood pressure in hypertensive subjects. *J Nutr* 137: 2405–2411
12. Castilla P, Echarri R, Davalos A et al. (2006) Concentrated red grape juice exerts antioxidant, hypolipidemic, and anti-inflammatory effects in both hemodialysis patients and healthy subjects. *Am J Clin Nutr* 84: 252–262
13. Egert S, Bosity-Westphal A, Seiberl J et al. (2009) Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. *Br J Nutr* 102: 1065–1074
14. Chopra M, Fitzsimons PE, Strain JJ et al. (2000) Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. *Clin Chem* 46: 1162–1170
15. Zern TL, Wood RJ, Greene C et al. (2005) Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. *J Nutr* 135: 1911–1917
16. Pourova J, Kottova M, Voprsalova M, Pour M (2010) Reactive oxygen and nitrogen species in normal physiological processes. *Acta Physiol (Oxf)* 198: 15–35
17. Gloire G, Legrand-Poels S, Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. *Biochem Pharmacol* 72: 1493–1505
18. Karlsen A, Paur I, Bohn SK (2010) Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. *Eur J Nutr* Feb 2: [Epub ahead of print].
19. Ishikawa Y, Sugiyama H, Stylianou E, Kitamura M (1999) Bioflavonoid quercetin inhibits interleukin-1-induced transcriptional expression of monocyte chemoattractant protein-1 in glomerular cells via suppression of nuclear factor-kappaB. *J Am Soc Nephrol* 10: 2290–2296
20. Moskaug JO, Carlsen H, Myhrstad M, Blomhoff R (2004) Molecular imaging of the biological effects of quercetin and quercetin-rich foods. *Mech Ageing Dev* 125: 315–324
21. Jung WJ, Sung MK (2004) Effects of major dietary antioxidants on inflammatory markers of RAW 264.7 macrophages. *Biofactors* 21: 113–117
22. Nair MP, Mahajan S, Reynolds JL et al. (2006) The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-kappa beta system. *Clin Vaccine Immunol* 13: 319–328
23. Lattig J, Bohl M, Fischer P et al. (2007) Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design. *J Comput Aided Mol Des* 21: 473–483
24. Formica JV, Regelson W (1995) Review of the biology of Quercetin and related bioflavonoids. *Food Chem Toxicol* 33: 1061–1080
25. Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. *Pharmacol Rev* 52: 673–751
26. Egert S, Boesch-Saadatmandi C, Wolffram S et al. (2010) Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. *J Nutr* 140: 278–284

27. Boots AW, Wilms LC, Swennen EL et al. (2008) *In vitro* and *ex vivo* anti-inflammatory activity of quercetin in healthy volunteers. *Nutrition* 24: 703–710
28. Bae SC, Jung WJ, Lee EJ et al. (2009) Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients. *J Am Coll Nutr* 28: 56–62
29. Hubbard GP, Wolfram S, Lovegrove JA, Gibbins JM (2004) Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. *J Thromb Haemost* 2: 2138–2145
30. Hubbard GP, Wolfram S, de Vos R et al. (2006) Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. *Br J Nutr* 96: 482–488
31. Janssen K, Mensink RP, Cox FJ et al. (1998) Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an *in vitro* and a dietary supplement study. *Am J Clin Nutr* 67: 255–262
32. Appel LJ, Brands MW, Daniels SR et al. (2006) Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. *Hypertension* 47: 296–308
33. Loke WM, Hodgson JM, Proudfoot JM et al. (2008) Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. *Am J Clin Nutr* 88: 1018–1025
34. Sanchez M, Galisteo M, Vera R et al. (2006) Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. *J Hypertens* 24: 75–84
35. Benito S, Lopez D, Saiz MP et al. (2002) A flavonoid-rich diet increases nitric oxide production in rat aorta. *Br J Pharmacol* 135: 910–916
36. Machha A, Achike FI, Mustafa AM, Mustafa MR (2007) Quercetin, a flavonoid antioxidant, modulates endothelium-derived nitric oxide bioavailability in diabetic rat aortas. *Nitric Oxide* 16: 442–447
37. Russo GL (2007) Ins and outs of dietary phytochemicals in cancer chemoprevention. *Biochem Pharmacol* 74: 533–544
38. Lee KW, Lee HJ (2006) The roles of polyphenols in cancer chemoprevention. *Biofactors* 26: 105–121
39. Pierini R, Gee JM, Belshaw NJ, Johnson IT (2008) Flavonoids and intestinal cancers. *Br J Nutr* 99 E Suppl 1: ES53–ES59
40. Neuhouwer ML (2004) Dietary flavonoids and cancer risk: evidence from human population studies. *Nutr Cancer* 50: 1–7
41. Murakami A, Ashida H, Terao J (2008) Multitargeted cancer prevention by quercetin. *Cancer Lett* 269: 315–325
42. Ramos S (2007) Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. *J Nutr Biochem* 18: 427–442
43. Lin J, Zhang SM, Wu K et al. (2006) Flavonoid intake and colorectal cancer risk in men and women. *Am J Epidemiol* 164: 644–651
44. Gates MA, Tworoger SS, Hecht JL et al. (2007) A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. *Int J Cancer* 121: 2225–2232
45. Simons CC, Hughes LA, Arts IC et al. (2009) Dietary flavonol, flavone and catechin intake and risk of colorectal cancer in the Netherlands Cohort Study. *Int J Cancer* 125: 2945–2952
46. Nöthlings U, Murphy SP, Wilkens LR et al. (2007) Flavonols and pancreatic cancer risk: the multiethnic cohort study. *Am J Epidemiol* 166: 924–931
47. Nöthlings U, Murphy SP, Wilkens LR et al. (2008) A food pattern that is predictive of flavonol intake and risk of pancreatic cancer. *Am J Clin Nutr* 88: 1653–1662
48. Bobe G, Weinstein SJ, Albanes D et al. (2008) Flavonoid intake and risk of pancreatic cancer in male smokers (Finland). *Cancer Epidemiol Biomarkers Prev* 17: 553–562
49. Wilson RT, Wang J, Chinchilli V et al. (2009) Fish, vitamin D, and flavonoids in relation to renal cell cancer among smokers. *Am J Epidemiol* 170: 717–729
50. Hirvonen T, Virtamo J, Korhonen P et al. (2001) Flavonol and flavone intake and the risk of cancer in male smokers (Finland). *Cancer Causes Control* 12: 789–796
51. Knekt P, Kumpulainen J, Jarvinen R et al. (2002) Flavonoid intake and risk of chronic diseases. *Am J Clin Nutr* 76: 560–568
52. Wang L, Lee IM, Zhang SM et al. (2009) Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women. *Am J Clin Nutr* 89: 905–912
53. World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) (2007) *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective*. Washington DC: AICR.
54. Hertog MG, Feskens EJ, Hollman PC et al. (1994) Dietary flavonoids and cancer risk in the Zutphen Elderly Study. *Nutr Cancer* 22: 175–184
55. Hertog MGL, Kromhout D, Aravanis C et al. (1995) Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. *Arch Intern Med* 155: 381–386
56. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J (1999) Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. *Urology* 54: 960–963
57. Kiesewetter H, Koscielny J, Kalus U et al. (2000) Efficacy of orally administered extract of red vine leaf AS 195 (*folia vitis viniferae*) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial. *Arzneimittelforschung* 50: 109–117
58. Lozoya X, Reyes-Morales H, Chavez-Soto MA et al. (2002) Intestinal anti-spasmodic effect of a phytoextract of *Psidium guajava* folia in the treatment of acute diarrheic disease. *J Ethnopharmacol* 83: 19–24
59. Harwood M, Danielewska-Nikiel B, Borzelleca JF et al. (2007) A critical review of the data related to the safety of quercetin and lack of evidence of *in vivo* toxicity, including lack of genotoxic/carcinogenic properties. *Food Chem Toxicol* 45: 2179–2205
60. Rietjens IM, Boersma MG, van der WH et al. (2005) Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. *Mutat Res* 574: 124–138
61. van der Woude H, Boersma MG, Alink GM et al. (2006) Consequences of quercetin methylation for its covalent glutathione and DNA adduct formation. *Chem Biol Interact* 160: 193–203
62. Albanes D, Heinonen OP, Huttunen JK et al. (1995) Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. *Am J Clin Nutr* 62: 1427–1430